Posts Tagged ‘ACNP’
Article
Letter from David Healy, MD to Peter J. Pitts Executive Summary of suicidal evidence not addressed by FDA In the light of Traci Johnson’s death on February 7th 2004, will FDA obtain Pfizer’s entire folder on the 1982 Hindmarch study in which healthy volunteers were given Zoloft, and make a statement as to whether data…
Read MoreInfomail Archive
Infomail 2004 News Stories on Human Research Protection and Commentary by Vera Hassner Sharav Dec 31: FDA to review “missing” drug company documents Dec 30: Family of Woman Killed by AIDS Drug Test Sues Doctors, Manufacturer Dec 30: Doctors, Too, Ask: Is This Drug Right? Dec 29: Bill would shield some drug firms from punitive…
Read MoreSenate Finance Committee Investigating FDA brain stimulation device approval – WSJ
Senate Finance Committee Investigating FDA brain stimulation device approval – WSJ Thu, 19 May 2005 Another major scandal is erupting about FDA’s approval decisions that contradict its medical officer’s safety concerns. The Senate Finance Committee is investigating what led the FDA to suddenly reverse its disapproval of Cyberonics’ brain stimulation device for the treatment of…
Read MoreNIMH Offers Grants to Study SSRI relation to Suicidality – FDA to Examine SSRI- Suicide in Adults
NIMH Offers Grants to Study SSRI relation to Suicidality_FDA to Examine SSRI- Suicide in Adults Mon, 14 Nov 2005 A fifteen year struggle by critics of the drug-centered treatment paradigm in psychiatry is being indirectly validated both by the FDA and the National Institute of Mental Health who are addressing the issue of SSRI and…
Read MoreReply to the ACNP’s Report on SSRI and Suicidal Behavior in Children – Leo
Reply to the American College of Neuropharmacology’s Report on SSRI and Suicidal Behavior in Children Jonathan Leo, Ph.D. Introduction The American College of Neuropsychopharmacology (ACNP) recently released an Executive Summary from its Task Force on SSRIs and Suicidal Behavior. The task force concluded that "taking Selective Serotonin Reuptake Inhibitors (SSRIs) or other new generation antidepressant…
Read MoreLilly to Add Suicide Warning to Strattera – Medicaid May shrink $5.5 Billion spending on Schizophrenia Drug
Lilly to Add Suicide Warning to Strattera – Medicaid May shrink $5.5 Billion spending on Schizophrenia Drug Thu, 29 Sep 2005 Reuters reports that Eli Lilly is adding a Black Box suicide warning to the Strattera label. Strattera has been promoted as a “non stimulant” treatment for ADHD. Since ADHD is loosely defined as attention…
Read MoreACNP Summary Report Criticized as "Junk Science"
ACNP Summary Report Criticized as “Junk Science” Sun, 25 Jan 2004 related links: Reply to ACNP Report – Jonathan Leo, Ph.D. FDA Sham Conflicts of Interest Policy Most of the National press coverage of the controversy swirling around the claims and counter claims about drug suicidal obsessive thinking and behavior in some children prescribed SSRI…
Read MoreAre SSRIs and Atypical Antidepressants Safe/ Effective for Children/ Adolescents/ Neonates?
Are SSRIs and Atypical Antidepressants Safe / Effective for Children / Adolescents/ Neonates? Wed, 2 Mar 2005 The American psychiatric establishment continues to operate within a “head in the sand” culture of denial when confronted with compelling evidence that has been scientifically replicated showing that their prescribing of antidepressants for children has been misguided. They…
Read More2 letters Re: Dr. Nemeroff Failure to Disclose Conflicts of Interest_WSJ
Success in academic psychiatry is not measured in the improvement of patients' mental health, but rather in quantifiable commercial tender.How many grants one brings to the university, how many publications one churns out each year, and how many corporate and professional advisory boards one serves on–and how much money one makes. The integrity of the…
Read MorePsychiatry’s Most Powerful Association Feeling the Heat_SCIENCE
Psychiatry’s most powerful and influential key opinion leaders who belong to the American College of Neuropsychopharmacology (ACNP) have been caught off guard. The ACNP leadership is scrambling to overcome the scorn it has received following public disclosure about multiple breaches of ethics and professional standards of conduct. The College and its journal, Neuropsychopharmacology, have become…
Read MoreTHE SCIENTIST–Former Head of UK Psychopharmacology says Money Didn’t Sway Dr. Nemeroff
A follow-up to news reports about the conflict of interest scandal that has engulfed not only Dr. Charles Nemeroff, former president and editor in chief of the official journal of the American College of Neuropsychopharmacology, but the College itself.
Read MoreACNP Journal Editor Quits Amid Exposure of Conflicts of Interest
A notice from The American College of Neuropsychopharmacology, the inner sanctum of biological–predominantly drug-centered psychiatry–informs the
membership of the resignation of Dr. Charles Nemeroff, the Editor-in-Chief of its journal, Neuropsychopharmacology.